Effects of statin therapy on clinical outcomes of survivors of acute myocardial infarction with severe systolic heart failure

Korea Acute Myocardial Infarction Registry Investigators

Research output: Contribution to journalArticle

3 Citations (Scopus)

Abstract

Objective Large randomized trials have failed to show a beneficial effect of statin treatment in chronic HF. The investigators tried to evaluate the long-term effects of statin therapy in patients with new onset heart failure (HF) following acute myocardial infarction (AMI). Methods Between January 2008 and December 2011, a total of 13,616 AMI patients were enrolled in the Korea Acute Myocardial Infarction Registry (KAMIR) which was a prospective, multicenter, nationwide, web-based database of AMI in Korea. From this database, we studied 1,055 patients with AMI who had newly developed severe acute HF [left ventricular ejection fraction 40%] and were discharged alive. The patients were divided into two groups, a statin group (n = 756) and a no-statin group (n = 299).We investigated the one-year major adverse cardiovascular events (MACEs), including all-cause mortality, MI, and any revascularization of each group. We then performed a propensity-score matched analysis. Results In the original cohort, one-year MACEs were similar between the two groups (16.5% vs. 14.7% in the statin or no-statin groups; p = 0.47). Propensity-score matching yielded 256 pairs, and in that population we observed comparable results in terms of MACEs (18.0% vs. 12.5% in the statin or no-statin groups, p = 0.11) and mortality (5.1% vs. 3.5% in the statin or no-statin groups, p = 0.51). Cox-regression analysis revealed that statin therapy was not an independent predictor for occurrence of a MACE [Hazard ratio (HR) 1.11, 95% CI 0.79â€" 1.57, p = 0.54] or all-cause mortality (HR 1.42, 95% CI 0.75â€"2.70, p = 0.28). Conclusion Statin therapy was not associated with a reduction in the long-term occurrence of MACEs or mortality in survivors of AMI with severe acute HF in this retrospective cohort study.

Original languageEnglish
Article numbere0144602
JournalPLoS One
Volume10
Issue number12
DOIs
Publication statusPublished - 2015 Dec 1

Fingerprint

Systolic Heart Failure
Hydroxymethylglutaryl-CoA Reductase Inhibitors
myocardial infarction
heart failure
Survivors
Myocardial Infarction
therapeutics
Korean Peninsula
Therapeutics
Heart Failure
Propensity Score
Mortality
Korea
cohort studies
long term effects
Hazards
regression analysis
Databases
Regression analysis
Stroke Volume

ASJC Scopus subject areas

  • Agricultural and Biological Sciences(all)
  • Biochemistry, Genetics and Molecular Biology(all)
  • Medicine(all)

Cite this

Effects of statin therapy on clinical outcomes of survivors of acute myocardial infarction with severe systolic heart failure. / Korea Acute Myocardial Infarction Registry Investigators.

In: PLoS One, Vol. 10, No. 12, e0144602, 01.12.2015.

Research output: Contribution to journalArticle

Korea Acute Myocardial Infarction Registry Investigators. / Effects of statin therapy on clinical outcomes of survivors of acute myocardial infarction with severe systolic heart failure. In: PLoS One. 2015 ; Vol. 10, No. 12.
@article{193e22dda6f64510932d45c52f7e0b80,
title = "Effects of statin therapy on clinical outcomes of survivors of acute myocardial infarction with severe systolic heart failure",
abstract = "Objective Large randomized trials have failed to show a beneficial effect of statin treatment in chronic HF. The investigators tried to evaluate the long-term effects of statin therapy in patients with new onset heart failure (HF) following acute myocardial infarction (AMI). Methods Between January 2008 and December 2011, a total of 13,616 AMI patients were enrolled in the Korea Acute Myocardial Infarction Registry (KAMIR) which was a prospective, multicenter, nationwide, web-based database of AMI in Korea. From this database, we studied 1,055 patients with AMI who had newly developed severe acute HF [left ventricular ejection fraction 40{\%}] and were discharged alive. The patients were divided into two groups, a statin group (n = 756) and a no-statin group (n = 299).We investigated the one-year major adverse cardiovascular events (MACEs), including all-cause mortality, MI, and any revascularization of each group. We then performed a propensity-score matched analysis. Results In the original cohort, one-year MACEs were similar between the two groups (16.5{\%} vs. 14.7{\%} in the statin or no-statin groups; p = 0.47). Propensity-score matching yielded 256 pairs, and in that population we observed comparable results in terms of MACEs (18.0{\%} vs. 12.5{\%} in the statin or no-statin groups, p = 0.11) and mortality (5.1{\%} vs. 3.5{\%} in the statin or no-statin groups, p = 0.51). Cox-regression analysis revealed that statin therapy was not an independent predictor for occurrence of a MACE [Hazard ratio (HR) 1.11, 95{\%} CI 0.79{\^a}€{"} 1.57, p = 0.54] or all-cause mortality (HR 1.42, 95{\%} CI 0.75{\^a}€{"}2.70, p = 0.28). Conclusion Statin therapy was not associated with a reduction in the long-term occurrence of MACEs or mortality in survivors of AMI with severe acute HF in this retrospective cohort study.",
author = "{Korea Acute Myocardial Infarction Registry Investigators} and Woo, {Jong Shin} and Hwang, {Seung Joon} and Kim, {Hyun Soo} and Kim, {Jin Bae} and Kim, {Woo Shik} and Kim, {Kwon Sam} and Jeong, {Myung Ho} and Weon Kim and Ahn, {Young Keun} and Chae, {Sung Chull} and Kim, {Jong Hyun} and Hur, {Seung Ho} and Kim, {Young Jo} and Seong, {In Whan} and Choi, {Dong Hoon} and Chae, {Jei Keon} and Hong, {Taek Jong} and Rhew, {Jae Young} and Kim, {Doo Il} and Chae, {In Ho} and Yoon, {Jung Han} and Koo, {Bon Kwon} and Kim, {Byung Ok} and Lee, {Myoung Yong} and Kim, {Kee Sik} and Hwang, {Jin Yong} and Cho, {Myeong Chan} and Oh, {Seok Kyu} and Lee, {Nae Hee} and Tahk, {Seung Jea} and Bae, {Jang Ho} and Seung-Woon Rha and Park, {Keum Soo} and Kim, {Chong Jin} and Han, {Kyoo Rok} and Ahn, {Tae Hoon} and Kim, {Moo Hyun} and Seung, {Ki Bae} and Chung, {Wook Sung} and Yang, {Ju Young} and Rhim, {Chong Yun} and Gwon, {Hyeon Cheol} and Park, {Seong Wook} and Koh, {Young Youp} and Joo, {Seung Jae} and Kim, {Soo Joong} and Jin, {Dong Kyu} and Cho, {Jin Man} and Kim, {Sang Wook} and Kim, {Jeong Kyung}",
year = "2015",
month = "12",
day = "1",
doi = "10.1371/journal.pone.0144602",
language = "English",
volume = "10",
journal = "PLoS One",
issn = "1932-6203",
publisher = "Public Library of Science",
number = "12",

}

TY - JOUR

T1 - Effects of statin therapy on clinical outcomes of survivors of acute myocardial infarction with severe systolic heart failure

AU - Korea Acute Myocardial Infarction Registry Investigators

AU - Woo, Jong Shin

AU - Hwang, Seung Joon

AU - Kim, Hyun Soo

AU - Kim, Jin Bae

AU - Kim, Woo Shik

AU - Kim, Kwon Sam

AU - Jeong, Myung Ho

AU - Kim, Weon

AU - Ahn, Young Keun

AU - Chae, Sung Chull

AU - Kim, Jong Hyun

AU - Hur, Seung Ho

AU - Kim, Young Jo

AU - Seong, In Whan

AU - Choi, Dong Hoon

AU - Chae, Jei Keon

AU - Hong, Taek Jong

AU - Rhew, Jae Young

AU - Kim, Doo Il

AU - Chae, In Ho

AU - Yoon, Jung Han

AU - Koo, Bon Kwon

AU - Kim, Byung Ok

AU - Lee, Myoung Yong

AU - Kim, Kee Sik

AU - Hwang, Jin Yong

AU - Cho, Myeong Chan

AU - Oh, Seok Kyu

AU - Lee, Nae Hee

AU - Tahk, Seung Jea

AU - Bae, Jang Ho

AU - Rha, Seung-Woon

AU - Park, Keum Soo

AU - Kim, Chong Jin

AU - Han, Kyoo Rok

AU - Ahn, Tae Hoon

AU - Kim, Moo Hyun

AU - Seung, Ki Bae

AU - Chung, Wook Sung

AU - Yang, Ju Young

AU - Rhim, Chong Yun

AU - Gwon, Hyeon Cheol

AU - Park, Seong Wook

AU - Koh, Young Youp

AU - Joo, Seung Jae

AU - Kim, Soo Joong

AU - Jin, Dong Kyu

AU - Cho, Jin Man

AU - Kim, Sang Wook

AU - Kim, Jeong Kyung

PY - 2015/12/1

Y1 - 2015/12/1

N2 - Objective Large randomized trials have failed to show a beneficial effect of statin treatment in chronic HF. The investigators tried to evaluate the long-term effects of statin therapy in patients with new onset heart failure (HF) following acute myocardial infarction (AMI). Methods Between January 2008 and December 2011, a total of 13,616 AMI patients were enrolled in the Korea Acute Myocardial Infarction Registry (KAMIR) which was a prospective, multicenter, nationwide, web-based database of AMI in Korea. From this database, we studied 1,055 patients with AMI who had newly developed severe acute HF [left ventricular ejection fraction 40%] and were discharged alive. The patients were divided into two groups, a statin group (n = 756) and a no-statin group (n = 299).We investigated the one-year major adverse cardiovascular events (MACEs), including all-cause mortality, MI, and any revascularization of each group. We then performed a propensity-score matched analysis. Results In the original cohort, one-year MACEs were similar between the two groups (16.5% vs. 14.7% in the statin or no-statin groups; p = 0.47). Propensity-score matching yielded 256 pairs, and in that population we observed comparable results in terms of MACEs (18.0% vs. 12.5% in the statin or no-statin groups, p = 0.11) and mortality (5.1% vs. 3.5% in the statin or no-statin groups, p = 0.51). Cox-regression analysis revealed that statin therapy was not an independent predictor for occurrence of a MACE [Hazard ratio (HR) 1.11, 95% CI 0.79â€" 1.57, p = 0.54] or all-cause mortality (HR 1.42, 95% CI 0.75â€"2.70, p = 0.28). Conclusion Statin therapy was not associated with a reduction in the long-term occurrence of MACEs or mortality in survivors of AMI with severe acute HF in this retrospective cohort study.

AB - Objective Large randomized trials have failed to show a beneficial effect of statin treatment in chronic HF. The investigators tried to evaluate the long-term effects of statin therapy in patients with new onset heart failure (HF) following acute myocardial infarction (AMI). Methods Between January 2008 and December 2011, a total of 13,616 AMI patients were enrolled in the Korea Acute Myocardial Infarction Registry (KAMIR) which was a prospective, multicenter, nationwide, web-based database of AMI in Korea. From this database, we studied 1,055 patients with AMI who had newly developed severe acute HF [left ventricular ejection fraction 40%] and were discharged alive. The patients were divided into two groups, a statin group (n = 756) and a no-statin group (n = 299).We investigated the one-year major adverse cardiovascular events (MACEs), including all-cause mortality, MI, and any revascularization of each group. We then performed a propensity-score matched analysis. Results In the original cohort, one-year MACEs were similar between the two groups (16.5% vs. 14.7% in the statin or no-statin groups; p = 0.47). Propensity-score matching yielded 256 pairs, and in that population we observed comparable results in terms of MACEs (18.0% vs. 12.5% in the statin or no-statin groups, p = 0.11) and mortality (5.1% vs. 3.5% in the statin or no-statin groups, p = 0.51). Cox-regression analysis revealed that statin therapy was not an independent predictor for occurrence of a MACE [Hazard ratio (HR) 1.11, 95% CI 0.79â€" 1.57, p = 0.54] or all-cause mortality (HR 1.42, 95% CI 0.75â€"2.70, p = 0.28). Conclusion Statin therapy was not associated with a reduction in the long-term occurrence of MACEs or mortality in survivors of AMI with severe acute HF in this retrospective cohort study.

UR - http://www.scopus.com/inward/record.url?scp=84961375033&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84961375033&partnerID=8YFLogxK

U2 - 10.1371/journal.pone.0144602

DO - 10.1371/journal.pone.0144602

M3 - Article

VL - 10

JO - PLoS One

JF - PLoS One

SN - 1932-6203

IS - 12

M1 - e0144602

ER -